Anti-SARS-CoV-2 RBD (Bamlanivimab), Humanized Antibody | A2292

The SARS-CoV-2 spike protein (S glycoprotein) is found on the outside of the virus particle and gives the coronavirus its crown-like appearance. The S glycoprotein mediates attachment of the virus particle to cell surface receptors such as ACE2, which facilitates viral entry into the host cell. S glycoprotein is an important target for vaccine development, antibody therapies, and diagnostic testing. The original monoclonal antibody against the S glycoprotein is currently being investigated in clinical trials of COVID-19 treatment.

A2292 | Anti-SARS-CoV-2 RBD (Bamlanivimab), Humanized Antibody DataSheet

Antibody Target: SARS-CoV-2 receptor binding domain (RBD) / spike protein

Target Alternative Name: Spike glycoprotein; S glycoprotein; Spike protein S1; Spike protein S2; Spike protein S2'; receptor binding domain [SARS-CoV-2]; RBD [SARS-CoV-2]

Tag Line: A humanized monoclonal antibody that binds to and inhibits the binding of the SARS-CoV-2 spike protein to cell surface receptors

Category: GM-CSF

Host:

Isotype: IgG

Species Reactivities: FALSE

Immunogen Sequence: FALSE

Accession #: P0DTC2

Gene ID: 43740568

Appearance: Liquid

Form:

Concentration: 1 mg/mL

Formulation: In PBS, pH 7.5

Purification: FALSE

Application: FALSE

Positive Control:

Application And Usages:

Country of Animal Origin: USA

Country of Manufacture: USA

Usage: For Research Use Only! Not to be used in humans.

Handling: The antibody solution should be gently mixed before use.

Western Blot Verified: FALSE

Immunocytochemistry Verified:

Immunofluorescence Verified: FALSE

Immunoprecipitation Verified: FALSE

FACS Verified:

ELISA Verified: FALSE

ChIP Verified: FALSE

Dot Blot Verified: FALSE

Flow Cytometry Verified: FALSE